Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT04038489
What this trial is testing

COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
University of Virginia
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Testing effectiveness (Phase 2)UnknownNCT04293276
What this trial is testing

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 41
Testing effectiveness (Phase 2)Study completedNCT05163106
What this trial is testing

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

Who this might be right for
Breast CancerHER2-negative Breast CancerER-positive Breast Cancer+3 more
University Hospital, Akershus 85
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Looking for participantsNCT07528716
What this trial is testing

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Who this might be right for
Breast Cancer
Fudan University 280
Large-scale testing (Phase 3)Study completedNCT00103233
What this trial is testing

Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network
Not applicableActive Not RecruitingNCT05036252
What this trial is testing

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

Who this might be right for
Breast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center 23
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)Ended earlyNCT01534455
What this trial is testing

Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)

Who this might be right for
Metastatic Breast Cancer
GBG Forschungs GmbH 43
Not applicableStudy completedNCT00896376
What this trial is testing

Trastuzumab in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Antoine Lacassagne 49
Not applicableStudy completedNCT02595762
What this trial is testing

Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche 110
Testing effectiveness (Phase 2)Looking for participantsNCT07612215
What this trial is testing

Elacestrant in Advanced Triple Positive Breast Cancer

Who this might be right for
ER Positive, HER2 Positive Breast Cancer
NYU Langone Health 50
Testing effectiveness (Phase 2)Looking for participantsNCT06178159
What this trial is testing

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Large-scale testing (Phase 3)Temporarily pausedNCT05503108
What this trial is testing

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Who this might be right for
Fasting Mimicking DietHER2-negative Breast CancerHormone Receptor-positive Breast Cancer+3 more
Leiden University Medical Center 10
Not applicableActive Not RecruitingNCT05132790
What this trial is testing

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Who this might be right for
Breast Cancer
Shengjing Hospital 24
Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Large-scale testing (Phase 3)Study completedNCT01964391
What this trial is testing

Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 174
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Not applicableStudy completedNCT05253911
What this trial is testing

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

Who this might be right for
HER2-positive Breast Cancer
iOMEDICO AG 49
Next Page